Skip to main content
Devonian Health Group Inc logo

Devonian Health Group Inc — Investor Relations & Filings

Ticker · GSD ISIN · CA2518341078 TSXV Manufacturing
Open in API
Filings indexed 598 across all filing types
Latest filing 2024-03-27 Regulatory Filings
Country CA Canada
Listing TSXV GSD

About Devonian Health Group Inc

https://groupedevonian.com/

Devonian Health Group Inc. is a clinical-stage botanical pharmaceutical company specializing in the development of novel prescription therapeutic solutions for unmet medical needs. The core business involves late-stage prescription botanical drugs targeting fibroinflammatory autoimmune diseases, with a focus on gastrointestinal, dermatological, and hepatologic conditions. The company utilizes a broad-based technology platform, originating from over 20 years of research, to develop therapies that target multiple cellular pathways and regulate genes linked to these diseases. Its pipeline includes the lead product candidate, Thykamine, currently in Phase 3 clinical trials. Devonian also develops high-value dermatological products alongside its core drug development activities.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate. It is a certification letter by the Interim CFO regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended January 31, 2024. The document does not contain actual financial data or substantive financial analysis but is an officer certification related to interim filings. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (3156 characters), and it is clearly a certification letter, not the interim report or MD&A itself.
2024-03-27 English
52-109FV2 - Certification of interim filings - CEO (F).pdf
Regulatory Filings Classification · 100% confidence The document is an attestation signed by the CEO regarding the interim financial report and management report for the period ended January 31, 2024. It explicitly states it is an attestation for an emerging issuer under Canadian National Instrument 52-109, confirming the accuracy and fair presentation of the interim financial documents. The text does not contain actual financial statements or substantive financial data but is a certification of the interim report's contents. According to the Certification Rule, such attestations or officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is 3657 characters, which is relatively short and consistent with a certification letter rather than a full report. Therefore, the correct classification is Regulatory Filings (RNS).
2024-03-27 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification by the CEO regarding the interim financial report and interim MD&A for the period ended January 31, 2024. It is a Form 52-109FV2 certification of interim filings for a venture issuer. The text does not contain the actual interim financial statements or substantive financial data but is a certification letter confirming the review and fair presentation of the interim filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (3162 characters), and it is clearly a certification, not the full interim report.
2024-03-27 English
Interim MD&A - French.pdf
Annual Report Classification · 95% confidence The document is titled 'ANNUAL INFORMATION FORM FOR THE YEAR ENDED DECEMBER 31, 2023' and dated March 27, 2024. It contains detailed sections such as corporate structure, business development, mineral reserves, risk factors, dividend policy, legal proceedings, capital structure, market price, directors and officers, corporate governance, audit and risk committee, and additional information. The content is comprehensive and covers a full fiscal year, including financial and operational details. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The document is consistent with an Annual Information Form, which is a detailed annual disclosure document often filed by Canadian companies and similar in purpose to an annual report. Given the detailed nature and the annual period covered, this aligns best with the Annual Report category (10-K), which covers full financial performance and company activity for the year. Therefore, the appropriate classification is 10-K with high confidence. FY 2023
2024-03-27 English
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Q2-2024 MANAGEMENT REPORT - FOR THE THREE AND SIX-MONTH PERIODS ENDED JANUARY 31, 2024' and contains detailed discussion and analysis of the company's activities, financial position, and operational results for the quarter and half-year periods ending January 31, 2024. It includes forward-looking statements, company profile, research and development updates, and product information. The content is consistent with a Management Discussion and Analysis (MD&A) report, which is typically classified under Management Reports (MDA). The document is substantive and contains financial and operational analysis rather than just an announcement or summary, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). Therefore, the appropriate classification is Management Reports (MDA).
2024-03-27 English
Interim financial statements/report – French.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled "États financiers intermédiaires résumés consolidés" which translates to "Condensed Interim Consolidated Financial Statements" for the three and six month periods ended January 31, 2024 and 2023. It contains detailed financial statements including consolidated statements of financial position, net income and comprehensive income, changes in equity, and cash flows. The notes indicate the financial statements are unaudited and prepared according to IFRS IAS 34, which governs interim financial reporting. The document includes substantive financial data and analysis for a period shorter than a full fiscal year (six months). Therefore, this document is an Interim / Quarterly Report (IR). H1 2024
2024-03-27 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.